**Ex vivo expression of chemokine receptors on cells surrounding cutaneous nerves in patients with HIV-associated sensory neuropathy**

Jenjira MOUNTFORD\(^a\), Fitri OCTAVIANA\(^b\), Riwanti ESTIASARI\(^b\), Denise DEWANTO SETIAWAN\(^b\), Ibnu ARIYANTO\(^c\), Silvia LEE\(^a,d\), Jessica GAFF\(^a\), Constance CHEW\(^e\), Connie JACKAMAN\(^a\), Peter KAMERMAN\(^a,f\), Catherine CHERRY\(^f,g,h\), Patricia PRICE\(^a,c,f\)

\(^a\) School of Biomedical Sciences, Curtin University, Bentley, Australia

\(^b\) Neurology Department, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia

\(^c\) Virology and Cancer Pathobiology Research Center, Universitas Indonesia, Jakarta, Indonesia

\(^d\) Department of Microbiology, Royal Perth Hospital, Perth, Australia

\(^e\) Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia

\(^f\) School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

\(^g\) Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Australia

\(^h\) Burnet Institute, Melbourne, Australia

**Disclosure of Interest Statement:** The project was funded by Curtin University and University of Indonesia. No pharmaceutical grants were received.

**Corresponding Author:**

A/Professor Patricia Price

School of Biomedical Science, Curtin University, Bentley, Australia

Tel: 618-92669716

Email: patricia.price@curtin.edu.au

**Short Title:** Chemokine receptors and HIV neuropathy

**Words:** 3466
Abstract

Objective: HIV-associated sensory neuropathy (HIV-SN) remains common in HIV+ individuals receiving anti-retroviral therapy (ART), even though neurotoxic anti-retroviral drugs (e.g. stavudine) have been phased out of use. Accumulating evidence indicates that the neuropathy is immune-mediated. We hypothesise that chemokines produced locally in the skin promote migration of macrophages and T-cells into the tissue, damaging cutaneous nerves causing HIV-SN.

Design: We assessed chemokine receptor expression on infiltrating CD14+ and CD3+ cells around cutaneous nerves in standardised skin biopsies from HIV-SN+ patients (n=5), HIV-SN- patients (n=9) and healthy controls (n=4).

Methods: The AIDS Clinical Trials Group Brief Peripheral Neuropathy Screen was used to assess Indonesian HIV+ patients receiving ART without stavudine (case definition: bilateral presence of at least one symptom and at least one sign of neuropathy). Distal leg skin biopsies were stained to visualise chemokine receptors; CCR2, CCR5, CXCR3, CXCR4, CX3CR1, infiltrating CD3+ and CD14+ cells and protein-gene-product 9.5 on nerves, using immunohistochemistry and 4-colour confocal microscopy.

Results: Intraepidermal nerve fibre density was variable in patients without HIV-SN and generally lower in those with HIV-SN. CX3CR1 was more evident on CD14+ cells whereas CCR2, CCR5, CXCR3 and CXCR4 were more common on CD3+ cells. Expression of CX3CR1, CCR2 and CCR5 was more common in HIV-SN+ patients than those without HIV-SN. CXCR3 and CXCR4 were upregulated in all HIV+ patients, compared with healthy controls.

Conclusion: Inflammatory macrophages expressing CX3CR1 and T-cells expressing CCR2 and CCR5 may participate in peripheral nerve damage leading to HIV-SN in HIV+ patients treated without stavudine. Further characterisation of these cells is warranted. (250 words).

Keywords: HIV-Sensory Neuropathy, chemokine receptors, CD3+ cells, CD14+ cells
Introduction

HIV-associated sensory neuropathy (HIV-SN) is a common neurologic manifestation of HIV and its treatment. Historically, neuropathy has been described in about 30% of treatment-naïve patients with advanced HIV disease [1, 2], and about 60% of patients on anti-retroviral therapy (ART) regimens that included zalcitabine, didanosine or stavudine [3, 4]. It is now accepted that these drugs are neurotoxic. Despite patients now starting treatment earlier and without known neurotoxic antiretroviral agents, HIV-SN remains a problem [5-7].

A pathological hallmark of HIV-SN is distal degeneration of long axons in a “dying back” pattern, which is associated with reduced intraepidermal nerve fibre density (IENFD), nerve fibre swelling, and mononuclear cell infiltration [8, 9]. HIV-infected and uninfected activated macrophages can infiltrate peripheral nerves, dorsal root ganglia (DRG) [10] and/or tissues adjacent to peripheral nerves, and release cytokines such as Tumour Necrosis Factor alpha (TNF-α), Interferon-gamma (IFN-γ) and Interleukin (IL)-1 and/or IL-17, which can cause axonal degeneration [11]. TNF-α injected into rat sciatic nerve stimulated neuropathic pain behaviour [12] and TNF-α mRNA levels were increased in peripheral nerve tissue from AIDS patients [13]. Furthermore, genetic association studies have linked polymorphisms and haplotypes from TNF and surrounding genes with increased risk of HIV-SN in Africans [14], Asians and Caucasians [15].

Chemokines produced in cutaneous tissues can bind to their receptors expressed on neuronal and inflammatory cells, initiating damage to the nerves. CCR5 and CXCR4 are coreceptors supporting HIV-1 entry [16]. CCR1, CCR2, CCR4, CCR5, CXCR4 and CX3CR1 are expressed on subpopulations of sensory neurons and their axons [17, 18]. CCR2, CCR5 and CXCR4 are upregulated in primary sensory neurons and adjacent non-neuronal cells following peripheral nerve injury in animal models [19, 20]. HIV-1 envelope glycoprotein 120 (gp120) may bind CCR5 and/or CXCR4 on nerve cells causing direct axonal damage [21], but there is no evidence of HIV infecting peripheral nerves in humans. In primary DRG cultures, gp120 mediated neuronal toxicity via TNF-α/TNF receptor (TNFR)-1 signalling [22]. CXCR4 and CCR5 ligation by CXCL12 and CCL5 (respectively) mimicked neurotoxicity induced by gp120 [22]. Administration of gp120 into rat sciatic nerve, upregulated CCL2/CCR2 and...
triggered hypernociception [23]. CCR2 expression was upregulated on primary sensory neurons and Schwann cells after peripheral nerve injury [24], and CCR2-knockout mice showed reduced pain behaviour following partial ligation of sciatic nerves [25]. CX3CL1 can recruit macrophage expressing CX3CR1. CX3CR1 was upregulated on spinal microglia and DRG glial satellite cells following peripheral nerve injury [26], and CX3CR1-deficient mice showed reduced neuropathic pain behaviour [27].

There is a reasonable consensus linking HIV-SN with a reduced IENFD [28, 29], but no studies have addressed whether HIV-SN is associated with critical chemokine signalling pathways. Here we present evidence on the ex vivo expression of chemokine receptors on infiltrating CD14+ and CD3+ cells around nerves in skin biopsies from HIV+ patients exposed to modern ART regimens that excluded the known neurotoxic agents. We believe we are the first to investigate chemokine signalling pathways and IENFD in this context. These results will enhance the knowledge of the underlying pathogenesis of HIV-SN in the modern era of HIV care.
Materials and Methods

Patients and controls

HIV+ patients treated at Cipto Mangunkusumo Hospital, Jakarta, Indonesia, were screened for SN using the AIDS Clinical Trials Group Brief Peripheral Neuropathy Screen (ACTG-BPNS), a validated tool based on detection of clinical signs (reduced/absent ankle reflexes or absent/diminished vibration sense) and symptoms (pain, aching, burning, pins and needles, or numbness) of neuropathy [30]. We used the standard ACTG-BPNS case definition for HIV-SN: bilateral presence of at least one clinical sign and at least one symptom. Patients had received antiretroviral therapy for at least 12 months (median: 4.7 years [range: 1 – 12]) and had never received stavudine. Biopsies from 14 HIV+ participants (HIV-SN+ n=5, HIV-SN- n=9) were used. Control biopsies were obtained from Asian volunteers from Jakarta (male, n=1) and Curtin University, Australia (females, n=3). All donors are described in Supplementary Table 1. The study was approved by the Ethics Committee of the Faculty of Medicine, University of Indonesia (579/UN2.F1/ETIK/2014) and validated by Curtin University (HR210-2015). All participants gave written informed consent.

Sample collection and preservation

Local anaesthetic was injected and 3mm punch skin biopsies were collected ~10cm above the lateral malleolous on the distal leg, under sterile conditions. Biopsies were placed in 4% Paraformaldehyde-Lysine-Periodate fixative for 12-24 hours at 4°C before transfer to glycerol-based cryoprotectant (20% glycerol, 20% 0.4M Sorrenson’s Phosphate Buffer and 60% dH2O) for storage at -20°C. Biopsies were cut perpendicular to the epidermal surface on a freeze cryostat sliding microtome (Microm HM550; Thermo Scientific, Waltham, MA) set at 50µM, placed into antifreeze (33% glycerol, 33% ethylene glycol and 10% 2x phosphate buffer and dH2O) and stored at -20°C for immunochemistry (IHC).

Immunochemical staining

Staining was performed in 24-well plates. Sections were bleached with 0.25% potassium permanganate (15 minutes, room temperature), washed with 1mL Tris-buffered saline (TBS) containing 0.1% Triton-X, and treated with 5% oxalic acid (2 minutes). Sections were then
blocked with Image-iT FX Signal Enhancer (Invitrogen, Carlsbad, CA) for 30 minutes. This solution was removed before the addition of primary antibodies.

To identify chemokine receptors on CD14\(^+\) cells, sections were treated (overnight, 4°C) with mouse-monoclonal IgG antibodies against CCR2, CCR5, CXCR3 or CXCR4 (5\(\mu\)g/ml; R&D Systems, Minneapolis, MN) or CX3CR1 (10\(\mu\)g/ml; Biolegend, San Diego, CA), biotinylated polyclonal sheep IgG anti-CD14 (R&D systems, Minneapolis, MN) and polyclonal rabbit IgG anti-protein-gene-product 9.5 (PGP9.5; 2\(\mu\)g/ml) to detect nerves (Abcam, Cambridge, MA). Sections were washed five times with TBS, followed by six 1-hour washes before adding secondary antibodies; goat anti-mouse IgG FITC (20\(\mu\)g/ml), donkey anti-rabbit IgG Dylight (5\(\mu\)g/ml; Abcam) and AlexaFluor\textsuperscript{®} fluorochrome streptavidin (20\(\mu\)g/ml; Invitrogen). Secondary antibodies were diluted in 2% donkey, goat and human serum and applied overnight at 4°C.

To identify chemokine receptors on CD3\(^+\) cells, sections were treated (overnight, 4°C) with polyclonal goat IgG against CCR2, CCR5, CXCR4 (20\(\mu\)g/ml) or CXCR3 (10\(\mu\)g/ml), mouse-polyclonal IgG anti-CD3 (10\(\mu\)g/ml; Novus Biologicals, Littleton, CO) and anti PGP9.5 (as above). Sections were washed as described above and treated with biotinylated donkey anti-goat IgG (20\(\mu\)g/ml; Abcam). Sections were blocked with 1% goat serum for 30 minutes before addition of AlexaFluor\textsuperscript{®} fluorochrome streptavidin (20\(\mu\)g/ml; Invitrogen), goat anti-mouse IgG FITC (20\(\mu\)g/ml) and donkey anti-rabbit IgG (5\(\mu\)g/ml; Abcam). Secondary antibodies were diluted in 1% goat serum and 2% donkey serum, and applied overnight at 4°C. Stained sections were washed 6 times, incubated with 4’,6-diamidino-2-phenylindole, dihydrochloride (10 minutes) (Invitrogen), washed twice with TBS, mounted using Shandon Immunount (Thermo Fisher Scientific, Waltham, MA) and coverslips (#1.5, Proscitech, Queensland, Australia) before viewing. One section stained only with secondary antibodies was included in each run as a negative control.

**Visualisation of sections using confocal microscopy**

Images were acquired using an inverted Nikon A1+ confocal microscope with NIS-Elements confocal software (Nikon Instruments, Tokyo, Japan). Images were collected at digital scan...
resolution 0.62\(\mu\)m/pixel, pixel dwell 4.8 with 1024 resolution using a 20x Plan Apo dry objective (N.A. 0.75). Sequential laser scanning was performed using four lasers; 405nm (450/50 filter), 488nm (525/50 filter), 561nm (595/50 filter) and 640nm (700/75 filter) to view nuclei, chemokine receptors, nerve fibres and CD14\(^+\) or CD3\(^+\) cells respectively. The position of the top and bottom of the image was recorded before multiple images were taken in a z-series, collected according to Nyquist criteria. Equivalent thresholds were applied across images to visualise nerves (white), chemokine receptors (red) and CD14\(^+\) or CD3\(^+\) (green). Chemokine receptors co-located with either CD14\(^+\) or CD3\(^+\) cells appeared yellow.

**Intraepidermal nerve fibre density (IENFD)**

NIS-Elements Advanced Research software (Nikon Instruments, Tokyo, Japan) was used to acquire three 0.5mm\(^2\) sections per biopsy (only 2 samples were available for one participant). Sections were coded and nerve fibres were counted by six investigators using standardised rules for IENFD quantification [31]. In brief, single IENF crossing the dermal-epidermal junction are counted with secondary branching excluded from quantification. The average count across the three sections per biopsy was multiplied by 2 to generate IENFD per mm\(^2\) area of skin for each participant (Supplementary Figure 1).

We computed Light’s \(\kappa\) for exact agreement (0 tolerance) between the six raters, treating rating as a weighted variable and using squared distance. A bootstrap 95% confidence interval (n = 1000 resamples) was calculated using the bias-corrected and accelerated bootstrap method. The analysis yielded a Light’s \(\kappa = 0.79\) (95%CI: 0.61 to 0.91); the point estimate indicating strong inter-rater agreement, with the confidence interval indicating moderate to strong agreement [32].
Results

Intraepidermal nerve fibre density was generally reduced in HIV-SN+ patients

HIV-SN+ \( (n=5) \) and HIV-SN- \( (n=9) \) patients were matched for age, height, time on ART and CD4\(^+\) T cell counts (Supplementary Table 1). Healthy controls \( (HC, n=4) \) were also matched with the patients by age and height. All donors were of South East Asian ancestry. Figure 1 shows confocal images from two HC (panels A and B), two HIV-SN- patients (panels C and D) and two HIV-SN+ patients (panels E and F) selected to represent the range seen in each group. Median (range) IENFD per square mm field were 11.2 (5.8 – 15.2), 5.8 (1.3 – 14.0) and 3.0 (0.8 – 9.7) in HC, HIV-SN- and HIV-SN+ groups, respectively. The IENFD tended to be reduced in HIV-SN+ patients compared with HC, but the study was not powered to find a significant difference (Supplementary Tables 1, 2, Supplementary Figure 1). A reduction in the length of nerve fibres within the epidermis of HIV-SN+ patients was common. CD14\(^+\) macrophages were visible in sections from HIV+ patients. Many were adjacent to blood vessels, scattered within cutaneous tissue or adjacent nerve fibres.

CX3CR1 was expressed on CD14\(^+\) cells adjacent to peripheral nerves in HIV-SN+ patients

Sections were stained to visualise expression of CX3CR1 on infiltrating CD14\(^+\) cells (Figure 1). CX3CR1 expression was extremely rare in the three sections from HC (panels A and B). They were also rare in sections from three HIV-SN- patients (e.g. panels C and D). Few CX3CR1\(^+\) cells were seen in two of three sections from HIV-SN+ patients (panels E and F). In all sections from HIV-SN+ patients, CX3CR1 was co-located with CD14 (yellow arrows) and was closely associated with the subepidermal nerve plexi (Figure 1, panels E and F). This is consistent with a role for the receptor in HIV-SN.

CCR2 is upregulated in HIV-SN+ skin and predominantly expressed by CD3\(^+\) cells

Sections were stained to visualise CCR2 on infiltrating CD14\(^+\) or CD3\(^+\) cells (Figure 2). Very few CCR2\(^+\) cells were evident in HC (e.g. panels A and B). Two of eight stained sections from HIV-SN- cases displayed detectable CCR2\(^+\) cells (e.g. panel D), whereas all seven sections
from five HIV-SN+ cases displayed CCR2 expression (e.g. panels E and F). The HIV-SN- patient expressing CCR2 most clearly (patient 11; not shown) had the lowest IENFD and a case review uncovered a history of Stevens Johnson Syndrome – an inflammation of the skin. The patient was excluded from further IHC. Most CCR2 was co-located with CD3 (panels D and F, yellow arrows). CD14+ cells were visible but rarely expressed CCR2 (panels A, C, E).

**CCR5 is upregulated and associated with peripheral nerves in HIV-SN+ skin sections**

Sections were also stained to visualise expression of CCR5 on infiltrating CD14+ or CD3+ cells (Figure 3). CCR5+ cells were very rare in HC (panels A and B). Isolated positive cells were seen in two of five samples from HIV-SN- (panels C and D) and five of five samples from HIV-SN+ patients, with some cells located close to nerve fibres (panels E and F). CCR5 was co-located with CD3 (yellow arrows, panels D and F), but not CD14 (panels A, C and E).

**CXCR3 was expressed by scattered CD3+ cells in all HIV+ patients**

CXCR3+ cells were visible in blood vessels present in some sections from all groups. CXCR3+ cells located closely with CD14+ cells but the two markers did not co-stain (Figure 4: panels A, C, E). In addition, variable numbers of CD3+ CXCR3+ cells were seen scattered in the tissues, so that some were adjacent to nerves in all eight sections from HIV-SN- and three sections from HIV-SN+ patients. Fewer positive cells were seen in samples from HC, so expression of this marker may be a consequence of HIV infection.

**CXCR4+ CD3+ cells were seen along the epidermis and the dermis in HIV+ patients**

CXCR4+ cells were seen in some but not all sections from HC (Figure 5. panels A and B). CXCR4 was expressed in all six sections from HIV-SN- patients (panels C and D) and three HIV-SN+ patients (panels E and F) and was distributed along the epidermis (panel C and F) or adjacent to blood vessels (panel E). Some larger cells expressed CXCR4 without CD14+ (panel E). CXCR4 was expressed on a subset of CD3+ cells in the dermis (panels D and F). This may reflect HIV disease rather than HIV-SN.
Discussion

We have developed a protocol that identifies cells and receptors that could contribute to the damage of small nerve fibres and form the basis of HIV-SN. The compilation of images into z-series allowed us to follow individual nerves as if they were distributed in the tissue in just two dimensions. Counts made by multiple observers blinded to the disease phenotype provide reliable quantification of IENFD (Supplementary Figure 1). The median IENFD at the distal leg of normal controls was 11.2 per mm². This is consistent with an earlier study with the reference range of 13.8±6.7 per mm² [33]. IENFD was generally reduced in HIV-SN+ patients and variable in those without HIV-SN. The wide range of nerve fibre densities in HIV-SN- patients may reflect early lesions not detected by the ACTG-BPNS. A recent longitudinal study of 150 Thai HIV+ individuals found IENFD measurements did not distinguish individuals with HIV-SN or signal the onset of neuropathic signs/symptoms [34]. However, IENFD decreases with increasing age [35]. Here all donors were 25 to 47 years old so any effect from age is likely to be minimal. We were also unable to assess associations with genotype [14, 36], but all participants were of South East Asian descent.

In addition to a reduction in the number of nerves in the epidermis, our methods demonstrate a reduction in cutaneous nerve fibre length in adults with HIV-SN (Figure 1, panels E) and in some HIV-SN- cases (Figure 1, panel C). It is unlikely that the loss of nerves reflects direct infection by HIV [9]. However, HIV-infected macrophages may have a primary role in nerve damage or may accumulate in response to debris from destroyed axons [37]. Our results show CD14⁺ macrophages were visible in all sections. These CD14⁺ macrophages may release pro-inflammatory cytokines causing axonal and DRG neuronal injury [38, 39]. A recent study has linked the loss of IENFD and increased recruitment of macrophages to DRG in Simian Immunodeficiency Virus-infected macaques [40]. We show macrophages adjacent to blood vessels, scattered within cutaneous tissues and adjacent to nerve fibres. This distribution is consistent with their extravasation and migration towards the nerves, a pattern observed in other chronic inflammatory neuropathies [41]. However, these CD14⁺ macrophages did not express CCR2, CCR5, CXCR3 or CXCR4 but did express CX3CR1.
CX3CR1+ monocyte/macrophage are expressed in low levels and are recruited in healing tissues [42]. CX3CL1/CX3CR1 signalling is implicated in the development of neuropathic pain in animal models [27, 43-45]. Our results show CX3CR1 was minimally expressed, but CX3CR1+ CD14+ macrophages were seen near the residual nerves in sections from HIV-SN+ patients. This supports a study showing increased expression of CX3CR1 by macrophages in the sciatic nerve proximal to a site of mechanical injury and in the corresponding DRG [26]. Furthermore in a spinal nerve ligation model, CX3CR1 expression was upregulated in spinal microglia, whilst membrane-bound levels of CX3CL1 were reduced [43]. The cleavage of CX3CL1 after nerve injury may initiate activation of the low affinity purinergic P2X7 receptor, leading to the release of the lysosomal cysteine protease cathepsin S from microglia. This may mediate neural–glial interaction and neuropathic pain behavior [46]. Accordingly, the gene encoding the P2X7 receptor, P2X7R, lies in a region of linkage disequilibrium with upstream genes P2X4R and CAMKK2 and single nucleotide polymorphisms and haplotypes within this block of genes were associated with HIV-SN in South Africans HIV+ individuals [47]. Other studies suggest downstream mechanisms of CX3CR1 via p38 mitogen-activated protein kinases [43] or extracellular signal-regulated protein kinase 5 [48] may activate microglia after nerve injury. Blockade or knockout of CX3CR1 impaired neuropathic pain behaviours and reduced hypersensitivity to thermal stimuli following peripheral nerve injury in animal models [27, 43, 44]. These considerations support our evidence that CX3CR1 could have a role in HIV-SN.

Our results show CCR2, CCR5, CXCR3 and CXCR4 were co-localised with CD3 but not CD14. T-lymphocytes were observed in nerves obtained from patients with inflammatory neuropathies [49]. An immunocytochemical study investigating mononuclear cells in sural nerve biopsies from 42 HIV- and HIV+ patients with various types of peripheral neuropathy found that 72% of infiltrating mononuclear cells were CD3+ [50]. T-cell infiltration into the spinal dorsal horn after nerve injury was also implicated in the development of pain-like hypersensitivity in rats [51]. CCR2 is critical in recruiting T-cells in responses to axonal injury of the central nervous system [52]. CCL2/CCR2 expression were upregulated by primary sensory neurons and Schwann cells after a sciatic nerve constriction injury [24]. CCL2/CCR2 was also upregulated by gp120 injected into rat sciatic nerve. This paralleled the...
development of mechanical hypernociception [23]. Accordingly, we found CCR2 was upregulated and expressed in five of five HIV-SN+ skin sections.

CCR5 and CXCR4 are co-receptors for HIV. CXCR4 was expressed in all HIV+ skin sections whilst CCR5 was more evident in skin sections from patients with SN, with some positive cells located near nerve fibres. In a study of chemokine receptors in HIV/gp120-induced neurotoxicity based on mixed neuronal/glial cerebrocortical cultures, gp120 utilized CCR5, CXCR4 or both to cause neurotoxicity [53]. Interestingly, CCL4 and CCL5 (ligands of CCR5) can inhibit gp120-induced neuronal death, whilst CXCL12 (the ligand of CXCR4) could alone, be neurotoxic. Moreover, CCR5 ligands could inhibit CXCR4/CXCL12-induced neurotoxicity [53]. Hence our finding linking CCR5 with HIV-SN may place the receptor in a complex cascade. For example; the binding of gp120 to CXCR4 on Schwann cells can cause the release of CCL5. CCL5 can stimulate the production of TNF–α by neuronal cells in DRG, leading to TNFR1-mediated neurotoxicity [22].

CXCR3 co-localized with CD3 in all HIV+ patients. CXCR3 plays role in the adaptive immune response to inflammation and viral infection [54]. Some CXCR3+ cells were located near damaged nerves. In patients with diabetic neuropathy, quantitative polymerase chain reaction and flow cytometric analyses showed that CXCR3+ CD8+ T-cells were recruited and infiltrated into affected tissues [55]. CXCR3 ligands, CXCL9, CXCL10 and CXCL11, released from Schwann cells can further recruit CXCR3+ CD8+ T-cell into sites of peripheral neuropathy [56]. Furthermore, Schwann cells can stimulate CD8+ T-cells to release TNF–α and Programmed death-ligand 1 (PD-1) leading to neuronal apoptosis [55]. In foetal neuronal cultures, ligation of CXCR3 and CXCL10 can increase intracellular calcium, which in turn increases membrane permeability and cytochrome c release. This activates caspase-9 which activates caspase-3, ultimately leading to neuronal apoptosis [56]. Caspase 3-dependent neuronal apoptosis cascades have been demonstrated in studies of gp120-induced neurotoxicity [22, 57].
Our study has some limitations. First, tissue samples were small, and sampling error remains a possible issue as we did not scan the entire biopsy. Second, we used one validated but simple clinical tool to distinguish patients with structural changes to the cutaneous nerves (HIV-SN+) from those without (HIV-SN-). We cannot exclude the possibility that some of our “SN free” HIV+ patients may have had early, sub-clinical peripheral nerve lesions that were not detected by this tool. Third, the presence of chemokine receptors in skin tissues does not prove that their signalling is critical. However, we have linked CD14+ macrophages expressing CX3CR1, and CD3+ T-cells expressing CCR2 and/or CCR5 with HIV-SN in skin sections from HIV+ individuals. The cells may have a role in the loss of nerves (evident from the IENFD) or may impact upon nerve function creating the characteristic signs and symptoms of HIV-SN (numbness, tingling, pain, reduced vibration sense, etc.). Expression of CXCR3 and CXCR4 was linked with HIV disease as these receptors were found in all sections from patients. Further investigation is needed with longitudinal studies including samples collected during earlier phases of HIV-SN.

Acknowledgments

We thank patients and controls who donated biopsies, Dr Graham Thom (Southbank Dermatologists) for collecting control skin biopsies, Dr Yanuar Ahmad for his help recruiting patients, Ms Fitri Rahmi Fadhilah in the laboratory, Dr Fera Ibrahin and Dr Budiman Bela for access to laboratory facilities at Universitas Indonesia and Professor John Papadimitriou for an expert review of our manuscript. The authors acknowledge the support of Curtin University and Curtin Health Innovation Research Institute, and the Victorian Operational Infrastructure Support Program for support from the Burnet Institute.
References


17. Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ. **Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. The Journal of Neuroscience** 2001; **21**:5027.


44. Bian C, Zhao Z-Q, Zhang Y-Q, Lü N, Shamji M. **Involvement of CX3CL1/CX3CR1 Signaling in Spinal Long Term Potentiation.** *PLoS ONE* 2015; **10**.

45. Kiguchi N, Kobayashi Y, Kishioka S. **Chemokines and cytokines in neuroinflammation leading to neuropathic pain.** *Current Opinion in Pharmacology* 2011; **12**:55-61.

46. Clark AK, Wodarski R, Guida F, Sasso O, Malcangio M. **Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor.** *Glia* 2010; **58**:1710-1726.


49. Winer J, Hughes S, Cooper J, Ben-Smith A, Savage C. **Gamma delta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy.** *Journal of Neurology* 2002; **249**:616.


53. Kaul M, Ma Q, Medders KE, Desai MK, Lipton SA. **HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection.** *Cell Death and Differentiation* 2006; **14**:296.


55. Tang W, Lv Q, Chen XF, Zou JJ, Liu Zm, Shi YQ. **CD8+ T Cell-Mediated Cytotoxicity toward Schwann Cells Promotes Diabetic Peripheral Neuropathy.** *Cellular Physiology and Biochemistry* 2013; **32**:827-837.


Figure 1. Representative confocal images showing expression of CX3CR1 and CD14 in skin from two HC (A, B), HIV-SN- (C, D) and HIV-SN+ (E, F) patients. Abundant thin intraepidermal nerve fibres run from the dermis innervating the basement membrane and epidermis in HC skin section. The median nerve count (IEFND) was 11.2 [range: 5.8 – 15.2] fibres per mm² skin area. IENFD was variable in HIV-SN- sections (5.8 [1.3 – 14.0]) and slightly lower in HIV-SN+ (3.0 [0.8 – 9.7]). CX3CR1 was rare in HC skin sections and minimally expressed skin sections from patients. However, CX3CR1 expression was closely associated with epidermal nerves in HIV-SN+ sections, and co-localised with CD14+ cells (E, F; yellow arrows). The white line represents 100µm.

Figure 2. Representative confocal images showing expression of CCR2 with CD14 (left) or CD3 (right) in skin from HC (A, B), HIV-SN- (C, D) and HIV-SN+ (E, F) patients. CCR2 expression was rare in HC. Two of eight stained sections from HIV-SN- patients had detectable CCR2+ cells, whereas seven of seven sections from five HIV-SN+ cases displayed CCR2. Some CCR2+ cells were located close to nerves. CCR2 was rarely expressed on CD14+ cells (E), but was seen on CD3+ cells (D, F; yellow arrows).

Figure 3. Representative confocal images showing expression of CCR5 with CD14 (left) or CD3 (right) in skin from HC (A, B), HIV-SN- (C, D) and HIV-SN+ (E, F) patients. CCR5+ cells were rare in sections from HC (A, B), but expression was up-regulated in sections from HIV+ patients; HIV-SN- (two of five) and HIV-SN+ (six of six). CCR5 was predominantly co-localised with CD3 (D, F; yellow arrows). Some CCR5+ cells were located close to nerve fibres in sections from HIV-SN+ patients (E, F).

Figure 4. Representative confocal images showing expression of CXCR3 with CD14 (left) or CD3 (right) in skin from HC (A, B), HIV-SN- (C, D) and HIV-SN+ (E, F) patients. CXCR3 was rare in HC, mostly surrounding dermal blood vessels. CXCR3 was highly expressed in sections from all HIV+ patients, and most commonly co-localised with CD3 (D, F; yellow arrows). An expanded red box (E) highlights the close proximity of CD14+ (green) and CXCR3+ (red) cells on the nerve. A yellow box (F) shows the co-localisation of CD3 and CXCR3 (yellow) adhering to a cutaneous nerve in a HIV-SN+ section.

Figure 5. Representative confocal images showing expression of CXCR4 with CD14 (left) or CD3 (right) in skin from HC (A, B), HIV-SN- (C, D) and HIV-SN+ (E, F) patients. CXCR4 was upregulated in the epidermis and the dermis of HIV+ patients, with mixed patterns of expression (C, D, E, F). CXCR4 was rarely expressed on CD14+ cells (A, C, E) but was seen on CD3+ cells (D, F; yellow arrows).
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
**Table 1:** Characteristics of patients and healthy controls (HC)

<table>
<thead>
<tr>
<th>Donor</th>
<th>BPNSTa</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Time on ART (years)</th>
<th>Last CD4 count (cell/μL)</th>
<th>IEFNDb (per mm²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>HIV-SN+</td>
<td>Female</td>
<td>33</td>
<td>158</td>
<td>7</td>
<td>406</td>
<td>1.6</td>
</tr>
<tr>
<td>Patient 2</td>
<td>HIV-SN+</td>
<td>Female</td>
<td>33</td>
<td>167</td>
<td>7.5</td>
<td>729</td>
<td>9.7</td>
</tr>
<tr>
<td>Patient 3</td>
<td>HIV-SN+</td>
<td>Male</td>
<td>34</td>
<td>175</td>
<td>5</td>
<td>714</td>
<td>3.0</td>
</tr>
<tr>
<td>Patient 4</td>
<td>HIV-SN+</td>
<td>Male</td>
<td>47</td>
<td>167</td>
<td>6.8</td>
<td>284</td>
<td>4.6</td>
</tr>
<tr>
<td>Patient 5</td>
<td>HIV-SN+</td>
<td>Male</td>
<td>45</td>
<td>167</td>
<td>3.5</td>
<td>300</td>
<td>0.8</td>
</tr>
<tr>
<td>Patient 6</td>
<td>HIV-SN-</td>
<td>Male</td>
<td>38</td>
<td>179</td>
<td>8.7</td>
<td>626</td>
<td>6.7</td>
</tr>
<tr>
<td>Patient 7</td>
<td>HIV-SN-</td>
<td>Female</td>
<td>41</td>
<td>150</td>
<td>1</td>
<td>435</td>
<td>6.6</td>
</tr>
<tr>
<td>Patient 8</td>
<td>HIV-SN-</td>
<td>Male</td>
<td>35</td>
<td>165</td>
<td>12</td>
<td>693</td>
<td>5.4</td>
</tr>
<tr>
<td>Patient 9</td>
<td>HIV-SN-</td>
<td>Female</td>
<td>32</td>
<td>165</td>
<td>3.6</td>
<td>385</td>
<td>9.0</td>
</tr>
<tr>
<td>Patient 10</td>
<td>HIV-SN-</td>
<td>Male</td>
<td>44</td>
<td>171</td>
<td>2.8</td>
<td>84</td>
<td>4.0</td>
</tr>
<tr>
<td>Patient 11</td>
<td>HIV-SN-</td>
<td>Male</td>
<td>36</td>
<td>168</td>
<td>1</td>
<td>566</td>
<td>1.3</td>
</tr>
<tr>
<td>Patient 12</td>
<td>HIV-SN-</td>
<td>Male</td>
<td>25</td>
<td>165</td>
<td>1.6</td>
<td>653</td>
<td>14.0</td>
</tr>
<tr>
<td>Patient 13</td>
<td>HIV-SN-</td>
<td>Male</td>
<td>34</td>
<td>166</td>
<td>2.2</td>
<td>386</td>
<td>5.2</td>
</tr>
<tr>
<td>Patient 14</td>
<td>HIV-SN-</td>
<td>Female</td>
<td>41</td>
<td>150</td>
<td>1</td>
<td>448</td>
<td>5.8</td>
</tr>
<tr>
<td>HC1</td>
<td>-</td>
<td>Female</td>
<td>28</td>
<td>158</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HC2</td>
<td>-</td>
<td>Female</td>
<td>33</td>
<td>162</td>
<td>-</td>
<td>-</td>
<td>11.2</td>
</tr>
<tr>
<td>HC3</td>
<td>-</td>
<td>Female</td>
<td>33</td>
<td>151</td>
<td>-</td>
<td>-</td>
<td>15.2</td>
</tr>
<tr>
<td>HC4</td>
<td>-</td>
<td>Male</td>
<td>37</td>
<td>169</td>
<td>-</td>
<td>-</td>
<td>5.8</td>
</tr>
</tbody>
</table>

*a* Brief Peripheral Neuropathy Screening Tool

*b* Inter Epithelial Nerve Fibre Density
Table 2: Summary of donor characteristics

<table>
<thead>
<tr>
<th>(BPNST)</th>
<th>N value</th>
<th>Male</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Time on ART (years)</th>
<th>Last CD4 (cell/μL)</th>
<th>IEFND (per mm²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-SN+</td>
<td>5</td>
<td>3</td>
<td>34 (33-47)</td>
<td>167 (158-175)</td>
<td>6.8 (3.5-7.5)</td>
<td>406 (284-729)</td>
<td>3.0 (0.8 – 9.7)</td>
</tr>
<tr>
<td>HIV-SN-</td>
<td>9</td>
<td>6</td>
<td>36 (25-44)</td>
<td>165 (150-179)</td>
<td>2.2 (1.0-12)</td>
<td>448 (84-693)</td>
<td>5.8 (1.3 – 14.0)</td>
</tr>
<tr>
<td>HC</td>
<td>4</td>
<td>1</td>
<td>33 (28-37)</td>
<td>160 (151-169)</td>
<td>n/a</td>
<td>n/a</td>
<td>11.2 (5.8 – 15.2)</td>
</tr>
</tbody>
</table>

Results are presented as median (range); n/a not applicable

a Fisher’s exact test (HIV-SN+ versus HIV-SN-), b Mann-Whitney test (HIV-SN+ versus HIV-SN-)

Figure 1. Mean intraepidermal nerve fibre count for each patient as determined by each rater